Launch of TechBio firm, Lucera, brings decision intelligence to drug development
Well-established pharmaceutical technology business of Molecular Health sold to consortium of life science and private equity investors to form Lucera
Advertisement
Lucera GmbH, a TechBio company utilizing its proprietary technology to transform pharmaceutical R&D and enhance development efficacy and efficiency through unique decision intelligence, announced the launch of its operations. The newly formed corporation is funded by a consortium of institutional and private investors, who acquired the pharmaceutical technology business of Molecular Health GmbH and established the new entity. Friedrich von Bohlen, PhD, has been appointed Chief Executive Officer (CEO) and Stephan Brock, PhD, is serving as Chief Technology Officer (CTO). Both are seasoned life sciences executives with extensive experience in precision medicine and drug development.
Lucera was formed to close the gap between biomedical data abundance and decision quality in drug development. While pharma R&D has access to more data, models, and AI tools than ever before, critical decisions still require biological context, mechanistic rationale, and evidence that can be tracked, understood, and defended. In response, Lucera helps transform fragmented biomedical data into mechanistic, traceable, decision-ready insights through Dataome®, Lucera’s proprietary, semantically integrated biomedical knowledge base that has been expertly curated for more than 15 years. It is combined with a Knowledge Graph that connects biomedical entities, relationships, and evidence across sources, modalities, and biological scales. All rights to this technology are owned exclusively by Lucera. The business has a proven commercial model, generating revenues from pharma, biotech, CROs, management consulting and investment company clients.
Friedrich von Bohlen, PhD, CEO of Lucera, said: “With Lucera, we have the proven technology and expertise at hand to enable highly informed decision-making in biopharma R&D and life science investing by providing our clients a thorough understanding of a new drug candidate all along its development path – from target or phenotype to clinical path to side effect profile. By making biological rationale, patient context, evidence gaps, and development risks more explicit, Lucera supports better probability-of-technical-success assessment, more focused cohort design, more efficient evidence generation, and more informed preclinical and clinical development planning. As shown through our proven track record, this superior level of decision quality allows drug developers and investors to be more successful in program prioritization, program planning and resource allocation.”
Lucera has an interdisciplinary team of 25 employees, who joined from Molecular Health and bring extensive experience in biomedical knowledge engineering, AI, computational biology, translational science, real-world evidence, drug development intelligence, and consulting. The company is based in Heidelberg, Germany and has an international client base.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.